PARP inhibitors: general consensus

[Maxone73]

PARP inhibitors have emerged as a targeted therapy for prostate cancer, especially in tumors with specific DNA repair defects. By exploiting synthetic lethality, these drugs can selectively kill cancer cells that lack the ability to repair DNA damage. Common targets include BRCA2 and PALB2 mutations, but other genes like ATM and CDK12 may also respond, provided both copies of the gene are inactivated.

While their potential is clear, the application of PARP inhibitors requires caution. Current diagnostic tests often produce unreliable results, and improved functional assays are urgently needed. There are also concerns about long-term side effects, such as an increased risk of myelodysplasia or leukemia. Ultimately, careful patient selection and better testing methods are essential to unlocking the full benefits of PARP inhibitors in prostate cancer care.

For ATM mutants like me: biallelic gene inactivate ATM can only be somatic, otherwise you would have ataxia.

ATR inhibitors can anyway help PARPi in case of mono allelic ATM mutation

prostatewarriors.com/2025/0...